VivoSeq
Other

Unverricht-Lundborg Disease

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Unverricht-Lundborg disease is an early-stage landscape with 2 programs across 2 companies. The most active players are UCB, Sanofi. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

2 programs

Phase 3Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Brivaracetam

UCB

Immunoglobulin

Sanofi

Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
Completed·UCB logoUCB·Phase 3·NCT00357669·50 enrolled
Intravenous Immunoglobulin for Unverricht-Lundborg Disease.
Unknown status·AAzienda Socio Sanitaria Territoriale di Mantova·Phase 3·NCT03351569·1 enrolled
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
Completed·UCB logoUCB·Phase 3·NCT00368251·56 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)